Economists around the world expect muted U.S. economic growth in the coming quarters, and some indicators have shown an increased likelihood of a 2025 recession in recent weeks. [ Sign up for ...
21h
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
Zacks Investment Research on MSN23h
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock UpNektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback